ClinicalTrials.gg
Active, not recruitingNCT05928598Updated Oct 15, 2026

Goals for Epilepsy Clinic Visits Trial

An interventional study of Survey questionnaires and Epilepsy Visit Planner in Drug Resistant Epilepsy, sponsored by University of Michigan. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Michigan · Not applicable, Interventional, and Health services research

How we know

Updated Oct 15, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.

Planned enrollment
12th of 67
152 · median 27
Started
2023
with 3 others
No phase
38 of 78
22 open now
Primary completion
2026-07
later than 3 of 33 live
Registered
51st of 78
by date

Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is the 12th largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2023, is one of 38 with no phase, reaches primary completion later than 3 of the 33 other live ones, and was the 51st registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Drug Resistant Epilepsy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the "Epilepsy Visit Planner") have improved outcomes compared to patients that do not receive the tool.

The project's hypotheses are:

  • Patients that receive the Epilepsy Visit Planner will have improved patient-provider communication compared to the non-planner group.
  • Patients that receive the Epilepsy Visit Planner will have improved quality of life scores.
  • The Epilepsy Visit Planner will score highly on process measures of feasibility and acceptability, demonstrating suitability for future larger scale study.

Additionally, there is a related survey project that is not part of the clinical trial and will not be included in this registration information.

03

Conditions studied

  • Drug Resistant Epilepsy

Keywords

  • Survey
  • Quality of life
  • Communication tool
  • Patient-provider communication
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria - Patient Participants:

  • Adults with drug-resistant epilepsy
  • Participants receiving care through the Epilepsy clinics at the University of Michigan

Exclusion Criteria - Patient Participants:

  • \<18 years old
  • Non-English speaking
  • Do not clearly have drug-resistant epilepsy
  • Moderate-to-severe cognitive impairment that precludes study questionnaire completion

Inclusion Criteria - Provider Participants:

-University of Michigan epilepsy providers

Exclusion Criteria - Provider Participants:

-Not University of Michigan epilepsy providers

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Other
    Standard care arm - patient participants

    This group will be enrolled first.

    Behavioral: Survey questionnaires

  • Experimental
    Intervention arm (Epilepsy Visit Planner) - patient participants

    This group will be enrolled after the standard care arm enrollment is completed.

    Behavioral: Survey questionnaires · Behavioral: Epilepsy Visit Planner

  • Other
    Intervention arm (Epilepsy Visit Planner) - provider participants

    Epilepsy providers will be recruited from the University of Michigan (approximately 10 providers).

    Behavioral: Questionnaires for Providers

Interventions

  • BehavioralSurvey questionnaires

    Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.

  • BehavioralEpilepsy Visit Planner

    Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner. Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.

  • BehavioralQuestionnaires for Providers

    Providers will be asked to complete a survey after the clinic visit for the intervention group.

06

What researchers measure

Primary outcomes

  1. Perceived Efficacy in Patient-Physician Interactions Questionnaire (PEPPI), difference in mean score between trial arms

    This is a 10-item measure with Likert scale (range 1-5 for each response) with a score range of 10-50 (higher score indicating higher perceived efficacy in communicating with providers).

    Time frame: Baseline

Secondary outcomes

  1. Perceived Involvement in Care (PICS), difference in mean score between trial arms

    This is a 13-item measure with binary agree/disagree responses (0 points for disagree and 1 point for agree) and higher scores reflecting a greater degree of perceived patient activity and involvement.

    Time frame: Baseline

  2. Quality of Life in Epilepsy (QOLIE-10) inventory, difference in mean score between trial arms

    This is a 10-item measure with Likert scale (range 1-5 for each response) with a score range of 10-50 (lower score indicates better health outcome).

    Time frame: 3 months after baseline visit

  3. Feasibility, assessed in intervention arm

    Three questions will be asked regarding if the Planner was completed, if the Planner was shared during the visit, and how the Planner impacted visit length. Both patient participants and provider participants will complete these questions.

    Time frame: Baseline - intervention arm only

  4. Acceptability of Intervention Measure, assessed in intervention arm

    There are 4 questions that will be completed by the patient participants and provider participants that evaluate the acceptability of the intervention. The question responses have a Likert scale from 1(completely disagree) to 5 (completely agree). There is a range from 5-25 with a higher score indicating a higher acceptability of the intervention tool.

    Time frame: Baseline - intervention arm only

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jul 2026, 33 months.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's 33 months is close to that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Sep 2026 → Jul 2026 and completion Jan 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Jul 3, 2023
StartActual
Sep 27, 2023
Primary completionActual
Jul 22, 2026was Sep 2026
CompletionEst.
Oct 20, 2026was Jan 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Primary completion
Sep 1, 2026→Jul 22, 2026 (actual)
Oct 15, 2026
Study completion
Jan 1, 2027→Oct 20, 2026
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 1, 2026→Jul 22, 2026 (now actual)
    Study completion Jan 1, 2027→Oct 20, 2026
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05928598
Responsible party
Chloe Hill (Assistant Professor of Neurology, University of Michigan) — Principal investigator
First posted
Jul 3, 2023
Start date
Sep 27, 2023
Primary completion
Jul 22, 2026
Completion
Oct 20, 2026 (estimated)
Last update
Oct 15, 2026

Study contacts

Chloe Hill, MD
principal investigator · University of Michigan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion